Adult female acne treated with spironolactone: a retrospective data review of 70 cases
The prevalence of acne in the adult population is increasing, particularly in women. Spironolactone regulates sebaceous gland activity by blocking androgen receptor.
To evaluate retrospectively the efficacy of spironolactone in women with acne.
Materials & methods
Data from 70 women of at least 20 years, treated for their acne between 2010 and 2015 with low-dose spironolactone (≤150 mg/day), were analysed. Remission was defined by the number of retentional lesions inferior or equal to five and inflammatory lesions inferior or equal to two on the face. Variables influencing the response were studied using the Cox model.
The mean age was 31.3 years; 39 (56%) women had prior courses of isotretinoin and 53 (76%) had an oral contraception prior to treatment. Remission data from a median treatment period of six months (95% CI: 4-9) were obtained from 47 (71%) women. Markers for a positive response to spironolactone were a high number of inflammatory lesions at inclusion (OR: 1.08; 95% CI: 1.03-1.13; p = 0.001) and relapse with previous isotretinoin (OR: 2.46; 95% CI: 1.09-5.54; p = 0.03). The marker for a negative response was an association with oral contraceptives containing first or second-generation progestin (OR: 2.77; 95% CI: 1.35-5.71; p = 0.005).
This retrospective data analysis confirms that the use of low doses of spironolactone is a valuable alternative in women with acne in whom oral isotretinoin has failed. Moreover, the analysis shows that first and second-generation oral contraceptives decrease the efficacy of spironolactone, confirming the interest of using two third or fourth-generation oral contraceptives.
Key wordsadult female acne spironolactone contraception isotretinoin progestin
Unable to display preview. Download preview PDF.
- 16.Kim GK, Del Rosso JQ. Oral spironolactone in post-teenage female patients with acne vulgaris: practical considerations for the clinician based on 31 current data and clinical experience. J Clin Aesthetic Dermatol 2012; 5: 37–50.Google Scholar
- 22.Dreno B, Bodokh I, Chivot M, et al. ECLA grading: a system of acne classification for every day dermatological practice. Ann Dermatol Venerol 1999; 126: 136–41.Google Scholar
- 23.Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Published: May 28, 2009 (v4.02: Sept. 15, 2009). Not cited.Google Scholar
- 29.Plovanich M, Weng QY, Mostaghimi A. Low Usefulness of Potassium Monitoring Among Healthy Young Women Taking Spironolactone for Acne. J Am Med Assoc Dermatol 2015; 151: 941–4.Google Scholar